Idal is taking on the leadership role for the Medical Affairs team for Medication Delivery Solutions (MDS) in addition to his current responsibilities across Medication Management Solutions (MMS), Pharmaceutical Systems (PS) and the Latin American region. In this position, Idal oversees from a medical perspective a robust portfolio of clinical development projects (evid gen), bus dev/ M&A and early innovation opportunities. He will continue to report to Executive Vice President and Chief Medical Officer, with dotted line reporting to WW President, MDS and WW President, MMS. He is also joining the MDS Management Committee and Worldwide Leadership Team. Managing a significant clinical development/ HEOR budget aimed to generate more than 20 peer reviewed publications within a 3-year period and to support a significant number of desired claims for key product/portfolios.

In addition to Global BU responsibilities, Idal will also be a member of the LATAM regional business leadership team and will be responsible to conceptualize, develop and implement BDX or cross-BU Medical Affairs strategies and programs on a regional level in close coordination with the BU Heads of Medical Affairs at Global and Regional level, as well as with the Heads of Central Medical Affairs functions. Idal was supporting the LATAM Region on an interim basis since 2020 and now the position was made official. In this position, Idal can interact and support the different BD BUs including Integrated Diagnostic Solutions (IVD, etc), Biosciences, MDS, Interventional Segment (Surgery, PI, Urology /Critical Care) regarding regional needs including ISS/Evidence Generation, Regulatory and Compliance issues, Interaction with KOLs, etc.

In his expanded role, Idal provides medical and scientific leadership to both the MMS and PS organizations through KOL engagement and partnership, evidence generation, innovation and industry influence. Idal is a member of both WW MMS and PS Leadership teams and continues to be part of the CMO’s leadership team. In this role, there is still significant time spent with regulatory submissions (e.g. 510K, CE mark, CER/ EU-MDR) and risk management activities (remediation, inspection/audit, field actions), including interactions with global regulatory bodies & notified bodies (FDA, MHRA, BSI, DEKRA, ANVISA, TGA, etc). Regarding the Pharma Systems BU, main activities involve Medical Affairs functional/organizational development, evidence generation planning for new products, interaction with other pharma/biologic companies, support to regulatory needs.Led the MA team throughout the Alaris System 510(k) clearance. H.P. Becton Quality Award Winner

Idal leads Medical Affairs Strategy, execute Medical Affairs activities and drives thought Leadership strategy, which will be created in close collaboration with members of the Medication Management Solutions Leadership Team. Idal and team lead and develop innovative integrated Medical Affairs programs and activities including lifecycle evidence generation management for MMS products and solutions. He also leads MA interactions with Research & Development for New Product Development and Innovation, and provides key insights for clinical product requirements for MMS and medical oversight for product medical safety and efficacy for MMS. In addition, Idal will also provide leadership for the Center for Safety and Clinical Excellence. Idal is a member of the WW MMS LT, the Medical Affairs Leadership Team (MALT) and the Clinical Claim and Data Review Board (CCDRB). Due to regulatory submissions (e.g. 510K, CE mark, CER/ EU-MDR) but also risk management activities (remediation, inspection/audit, field actions), Idal has significant experience working with global regulatory bodies & notified bodies (FDA, MHRA, BSI, DEKRA, ANVISA, TGA, etc). In the last years, a relevant percentage of his time was spent with oversight of risk assessment, patient safety and quality assurance/ compliance activities.

July/2022 - appointed Vice-Chair of the BOD

Baxter has recently announced a new commercial/leadership reorganization; my role reports directly (solid line) to Baxter’s CSO and dotted line to GM, Medication Delivery GBU and I am retaining my therapeutic area leader roles and responsibilities. Member of Baxter’s Global Leadership Team (GLT)’Member of Global Science and Technology (GST) Leadership TeamMember of Med Delivery GBU Leadership TeamMember of Global I&D CouncilMember of R&D Council2016 BaxSTAR Winner “Outstanding Innovation Award”

Therapeutic Area Leader for the Fluid Systems Franchise (>$2B)  Reported to Global VP Medical Affairs, Hospital Products by April 2016 (new reorg being implemented with consolidation of 2 Business Units – Hospital Products & Renal)  Part of the Extended Global CSO leadership team  Manages a team of 11 pharmacists & nurses Member of Fluid Systems (FS) Franchise Leadership Team; Global Labeling Committee (GLC), Strategy Council & Governance team Responsible for medical strategy to support new product launches or geographical expansion; implements medical education programs, advisory boards & publication plans. Current areas of focus have been: Medication Errors Prevention, Elastomeric devices (OPAT – Outpatient Antimicrobial Therapy & CRC – Colorectal Cancer ), Bloodstream Infections Reduction & Fluid Management (approx. 30 publications - posters/abstracts/manuscripts - were submitted, presented or published in 2015 as result of IIR or Baxter sponsored programs in partnership with Market Access & HECON teams).  Provides input on creation of promotional and scientific communication materials; part of adprom medical review team & sign off for important customer letters, medical information inquiries when requested by the Medical Information department.  Provides medical review for Business Development, Ventures & R&D innovation teams Clinical Evidence Council (CEC) Lead to discuss and approve grants for Investigator-Initiated Research proposals & responsible for Baxter-sponsored clinical research strategy in Fluid Systems – interacting with Clinical Development teams Medical reviewer and approver to HHAs, FCAs, Risk Management docs, pFMEAs, CERs, and responses to MOHs etc.  Interacts with Health Authorities (e.g. FDA, MHRA, ANVISA-Brazil), other stakeholder organizations and acts as spokesperson 2015 BaxSTAR Winner “Stellar Award” (April/2016) - awarded to the team enabling the Sigma V8 Launch

 Reported to Global VP Medical Affairs, Hospital Products and is part of the Extended Global CSO (Chief Scientific Officer) leadership team  Managed a team of 16 people (for some time was also the interim lead for 2 US MSLs) - nurses, pharmacists & medical director Member of FS I&D Council  Member of Baxter’s Global Labeling Committee (GLC) Provided medical support for R&D innovation road mapping and technology assessments (due diligence) for BD team and Baxter Ventures  Responsible to capture and review investigator-initiated trials aligned with business strategy to be reviewed and funded by the Clinical Evidence Council Provided medical support for Baxter R&D top projects including workflows enhancement, formative/summative studies, safety assessments/risk-benefit analyses, labeling and training review, etc. Provides adprom medical review (printed & digital media campaigns) Provide medical support for FCAs, CER review, responses to MOHs etc. Interacted with Clinical Development team to propose investigator-initiated and Baxter-sponsored clinical research strategy  Responsible for medical strategy to support new product launches or geographical expansion; implements advisory boards & publication plans  Interacted with Health Authorities (e.g. FDA, HSA) and acted as spokesperson (with some media participation and published interviews)

 Reports to VP Med Affairs and interacts with Global therapeutic area leaders and is part of extended Global R&D leadership team Expanded his experience in Emerging Markets after visiting, training and participating in specific initiatives in almost all LA countries including early stage markets  Interacted with Global/Regional Marketing teams & Mkt research organizations teams to create, revise and implement market research projects (focus on Nutrition business) across LA region Proposed, approved and implemented a multinational post-marketing clinical registry for a product to enroll 600 patients ($ 800K project).  Provides medical/scientific evaluation for new product opportunities/licensing proposed by local and regional BD teams Seeking and evaluating IIS (investigator-initiated studies) opportunities in LA and Canada Interacts with and train Baxter sales force and/or distributors’ reps (early stage markets) Spokesperson: Participated in media initiatives in 2011 including Radio and TV interviews (Mexico) related to therapeutic areas of interest & lectures to health authorities mainly in early-stage markets Implemented integrated initiatives involving LA and Canada KOLs (speaker training, summits) Proposed an AdProm approval process harmonization across the region (currently in progress) Implemented speaker training for different products and multiplied the regional speaker bureaus

 Reported to the Global VP Medical Affairs – Medication Delivery Business Unit Revised all promotional campaigns and worked with Global marketing team to create global campaigns focused on Emerging Markets needs and barriers Introduced an on-distance training program (Webex-based) focused on key products to product specialists and managers Supported (proposed and revised all scientific contents and modules) a Regional e-learning platform initiative to train (on boarding) and periodically evaluate the sales force  Participated in several local (LA countries) congresses and meetings as invited speaker; visited customers and hospitals Participated in the hiring and on boarding process that filled medical affairs positions at the key countries Proposed and implemented advisory board meetings for 2 key franchises (Fluid Systems and Specialty Pharmaceuticals)

 Responsible for the Medical affairs activities at Brazilian subsidiary – managed the entire Medication Delivery (Hospital) and Bioscience (Immunoglobulins, Albumin, Fibrin Sealant, PCC, Vaccine – Meningococcal B) portfolio and provided scientific/medical support to Reg Affairs, GAPP, B2B projects Active participation in Oliclinomel’s Launch (Parenteral nutrition RTU bag) – including marketing plan activities, market research/focus groups activities (product positioning), promotional material development, lectures (speaker) and roadshows – a business with significant growth per year since then (currently a new version is in the market) Supported content development (evidence-based and market-oriented) of scientific materials (new campaigns) for Biosurgery (stratifying by surgical specialties) and for other two important business units (IV and Nutrition)  Supported and sponsored the First National Registry of Parenteral Nutrition (Prospective, observational study to understand parenteral nutrition (PN) use in ICUs and patients profiling) – presented as poster in “Parenteral nutrition in the intensive care unit: can we deliver better care to our patients? Preliminary results from a multicenter, prospective, cohort study - Critical Care 2007, 11(Suppl 2): P157 (22 March 2007)”  Revitalized and re-launched the “Biosurgery Business “(re-launch of Tisseel and 3 new product registrations e.g. Coseal and Floseal) : + 243% in net sales growth and + 256% in gross profit % growth in 3 years) with only 2 dedicated product specialists in Sao Paulo City and a solid strategy dedicated to target surgical specialties; Assessed, trained and expanded the number of new distributors for Biosurgery Identified opportunities (drug/molecule) for new B2B agreements (with “major pharma” companies) and trained other companies’ teams;